Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P62805 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11971165 | 0.80 | BRD4 (0.33) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL11971209 | 0.76 | KDM4E (0.36) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11971380 | 0.73 | CHEK1 (0.47) | MAPT | |
| SCHEMBL11971168 | 0.68 | — | — | |
| SCHEMBL27945625 | 0.66 | PRMT5 (0.39) | — | |
| SCHEMBL27243496 | 0.66 | MAPK1 (0.38) | KDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL826742 | 0.60 | SMN1; SMN2 (0.41) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16110414 | 0.59 | RAB9A (0.46) | KDM4EALDH1A1BRD4NPC1RAB9A | |
| SCHEMBL11971219 | 0.59 | PDE2A (0.43) | BRD4H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | |
| SCHEMBL16572422 | 0.57 | PDE10A (0.37) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598155-B2 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | PFIZER INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | GRIK5, GRIN2C, BDNF | KDM4E 3588/4885ALDH1A1 545/4885BRD4 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.